Release Date: December 7, 2007
Expiration Date: December 1, 2008
This program is designed for primary care physicians we will provide an overview of the epidemiology and pathophysiology of diabetic retinopathy, which is a devastating complication of diabetes, costing millions of dollars in lost wages and requiring extensive medical care. We will also give you a detailed look at the progression of glaucoma, a major problem for our nation's aging population.
This program is designed for primary care physicians who would like to educate patients newly diagnosed with diabetes about the prevention and treatment of diabetic retinopathy and glaucoma.
At the conclusion of this activity, participants should be able to:
- Describe, define and discuss the epidemiology and pathophysiology of diabetic eye disease and glaucoma.
- Cite current and emerging treatment options for patients diagnosed with diabetic eye disease and/or glaucoma.
- Integrate results from major clinical trials related to treatment of patients with the diabetic eye disease and glaucoma.
- Identify patients who are at risk of developing diabetic eye disease or glaucoma.
- Educate the patient about the appropriate disease management.
This activity has been reviewed and is acceptable for up to 2 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 12/01/07. Term of approval is for one-year from this date, with option for yearly renewal.
Suber S. Huang, MD, MBA (click to read bio)
Philip F. and Elizabeth G. Searle - Suber Huang MD Professor of Ophthalmology
Case Western Reserve University
Vice Chairman of the Department of Ophthalmology
Director of Vitreoretinal Diseases and Surgery
University Hospitals Case Medical Center
Mathew W. MacCumber, MD, PhD (click to read bio)
Associate Chairman for Research
Department of Ophthalmology
Rush University Medical Center
Disclosure of Affiliations and Significant Relationships
Dr. Huang has received consulting fees from Bausch & Lomb and Surmodics. He has also received honoraria related to formal advisory activities from Genentech.
Dr. MacCumber has received consulting fees from Genentech, Novartis, and Allergan.
There are no fees for participating in or receiving credit for this activity.
To Obtain Credit:
- The release date for this activity is December 7, 2007. The expiration date is December 1, 2008.
- After viewing the full synchronized slide-and-audio presentation you will have the opportunity to electronically submit a post-test and evaluation via the Internet in order to receive credit.
- In order to receive credit you must receive an examination test score of 80% or better and complete the evaluation questions.
- Once you have successfully completed the examination & evaluation, a certificate will be automatically generated.
- You may retake the post-test an unlimited number of times in order to successfully receive credit.
|This activity is supported by a subcontract from the National Institutes of Health. It is the policy of the American Retina Foundation to adhere to ACCME Essential Areas, Policies and Standards for Commercial Support in order to ensure fair balance, independence, objectivity and scientific rigor in all its sponsored programs.